145 related articles for article (PubMed ID: 38435424)
1. Enhanced potency of immunotherapy against B-cell precursor acute lymphoblastic leukemia by combination of an Fc-engineered CD19 antibody and CD47 blockade.
Schewe DM; Vogiatzi F; Münnich IA; Zeller T; Windisch R; Wichmann C; Müller K; Bhat H; Felix E; Mougiakakos D; Bruns H; Lenk L; Valerius T; Humpe A; Peipp M; Kellner C
Hemasphere; 2024 Feb; 8(2):e48. PubMed ID: 38435424
[TBL] [Abstract][Full Text] [Related]
2. An Fc-engineered CD19 antibody eradicates MRD in patient-derived
Schewe DM; Alsadeq A; Sattler C; Lenk L; Vogiatzi F; Cario G; Vieth S; Valerius T; Rosskopf S; Meyersieck F; Alten J; Schrappe M; Gramatzki M; Peipp M; Kellner C
Blood; 2017 Sep; 130(13):1543-1552. PubMed ID: 28698205
[TBL] [Abstract][Full Text] [Related]
3. Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL.
Müller K; Vogiatzi F; Winterberg D; Rösner T; Lenk L; Bastian L; Gehlert CL; Autenrieb MP; Brüggemann M; Cario G; Schrappe M; Kulozik AE; Eckert C; Bergmann AK; Bornhauser B; Bourquin JP; Valerius T; Peipp M; Kellner C; Schewe DM
Blood; 2022 Jul; 140(1):45-57. PubMed ID: 35452517
[TBL] [Abstract][Full Text] [Related]
4. Engineering of CD19 Antibodies: A CD19-TRAIL Fusion Construct Specifically Induces Apoptosis in B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Cells In Vivo.
Winterberg D; Lenk L; Oßwald M; Vogiatzi F; Gehlert CL; Frielitz FS; Klausz K; Rösner T; Valerius T; Trauzold A; Peipp M; Kellner C; Schewe DM
J Clin Med; 2021 Jun; 10(12):. PubMed ID: 34203833
[TBL] [Abstract][Full Text] [Related]
5. Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages.
Zeller T; Lutz S; Münnich IA; Windisch R; Hilger P; Herold T; Tahiri N; Banck JC; Weigert O; Moosmann A; von Bergwelt-Baildon M; Flamann C; Bruns H; Wichmann C; Baumann N; Valerius T; Schewe DM; Peipp M; Rösner T; Humpe A; Kellner C
Front Immunol; 2022; 13():929339. PubMed ID: 36389667
[TBL] [Abstract][Full Text] [Related]
6. G protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20/PI3Kδi dual therapy.
Ribeiro ML; Profitós-Pelejà N; Santos JC; Blecua P; Reyes-Garau D; Armengol M; Fernández-Serrano M; Miskin HP; Bosch F; Esteller M; Normant E; Roué G
Front Immunol; 2023; 14():1130052. PubMed ID: 37153563
[TBL] [Abstract][Full Text] [Related]
7. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance.
Upton R; Banuelos A; Feng D; Biswas T; Kao K; McKenna K; Willingham S; Ho PY; Rosental B; Tal MC; Raveh T; Volkmer JP; Pegram MD; Weissman IL
Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34257155
[TBL] [Abstract][Full Text] [Related]
8. Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody.
Gehlert CL; Rahmati P; Boje AS; Winterberg D; Krohn S; Theocharis T; Cappuzzello E; Lux A; Nimmerjahn F; Ludwig RJ; Lustig M; Rösner T; Valerius T; Schewe DM; Kellner C; Klausz K; Peipp M
Front Immunol; 2022; 13():957874. PubMed ID: 36119088
[TBL] [Abstract][Full Text] [Related]
9. Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab.
Baumann N; Arndt C; Petersen J; Lustig M; Rösner T; Klausz K; Kellner C; Bultmann M; Bastian L; Vogiatzi F; Leusen JHW; Burger R; Schewe DM; Peipp M; Valerius T
Front Immunol; 2022; 13():949140. PubMed ID: 36052078
[TBL] [Abstract][Full Text] [Related]
10. Leukemia escape in immune desert: intraocular relapse of pediatric pro-B-ALL during systemic control by CD19-CAR T cells.
Willier S; Raedler J; Blaeschke F; Stenger D; Pazos Escudero M; Jurgeleit F; Grünewald TGP; Binder V; Schmid I; Albert MH; Wolf A; Feuchtinger T
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32938628
[TBL] [Abstract][Full Text] [Related]
11. The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.
Carol H; Szymanska B; Evans K; Boehm I; Houghton PJ; Smith MA; Lock RB
Clin Cancer Res; 2013 Apr; 19(7):1795-805. PubMed ID: 23426279
[TBL] [Abstract][Full Text] [Related]
12. CCR7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma.
Schomer NT; Jiang ZK; Lloyd MI; Klingemann H; Boissel L
Cytotherapy; 2022 Aug; 24(8):827-834. PubMed ID: 35400595
[TBL] [Abstract][Full Text] [Related]
13. A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.
Robinson HR; Qi J; Cook EM; Nichols C; Dadashian EL; Underbayev C; Herman SEM; Saba NS; Keyvanfar K; Sun C; Ahn IE; Baskar S; Rader C; Wiestner A
Blood; 2018 Aug; 132(5):521-532. PubMed ID: 29743179
[TBL] [Abstract][Full Text] [Related]
14. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
[TBL] [Abstract][Full Text] [Related]
15. CD47 limits antibody dependent phagocytosis against non-malignant B cells.
Gallagher S; Turman S; Lekstrom K; Wilson S; Herbst R; Wang Y
Mol Immunol; 2017 May; 85():57-65. PubMed ID: 28208074
[TBL] [Abstract][Full Text] [Related]
16. Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodies.
Matlawska-Wasowska K; Ward E; Stevens S; Wang Y; Herbst R; Winter SS; Wilson BS
Leukemia; 2013 Jun; 27(6):1263-74. PubMed ID: 23307031
[TBL] [Abstract][Full Text] [Related]
17. Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia.
Colomar-Carando N; Gauthier L; Merli P; Loiacono F; Canevali P; Falco M; Galaverna F; Rossi B; Bosco F; Caratini M; Mingari MC; Locatelli F; Vivier E; Meazza R; Pende D
Cancer Immunol Res; 2022 Mar; 10(3):291-302. PubMed ID: 35078821
[TBL] [Abstract][Full Text] [Related]
18. Chimeric, divalent and tetravalent anti-CD19 monoclonal antibodies with potent in vitro and in vivo antitumor activity against human B-cell lymphoma and pre-B acute lymphoblastic leukemia cell lines.
Liu XY; Pop LM; Tsai L; Pop IV; Vitetta ES
Int J Cancer; 2011 Jul; 129(2):497-506. PubMed ID: 20878959
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia.
Caracciolo D; Riillo C; Ballerini A; Gaipa G; Lhermitte L; Rossi M; Botta C; Duroyon E; Grillone K; Gallo Cantafio ME; Buracchi C; Alampi G; Gulino A; Belmonte B; Conforti F; Golino G; Juli G; Altomare E; Polerà N; Scionti F; Arbitrio M; Iannone M; Martino M; Correale P; Talarico G; Ghelli Luserna di Rorà A; Ferrari A; Concolino D; Sestito S; Pensabene L; Giordano A; Hildinger M; Di Martino MT; Martinelli G; Tripodo C; Asnafi V; Biondi A; Tagliaferri P; Tassone P
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33597219
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia.
Magnani CF; Mezzanotte C; Cappuzzello C; Bardini M; Tettamanti S; Fazio G; Cooper LJN; Dastoli G; Cazzaniga G; Biondi A; Biagi E
Hum Gene Ther; 2018 May; 29(5):602-613. PubMed ID: 29641322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
